+

PE20060746A1 - Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3 - Google Patents

Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3

Info

Publication number
PE20060746A1
PE20060746A1 PE2005001440A PE2005001440A PE20060746A1 PE 20060746 A1 PE20060746 A1 PE 20060746A1 PE 2005001440 A PE2005001440 A PE 2005001440A PE 2005001440 A PE2005001440 A PE 2005001440A PE 20060746 A1 PE20060746 A1 PE 20060746A1
Authority
PE
Peru
Prior art keywords
oxo
treatment
pde3 inhibitor
pharmaceutical compositions
cyclohex
Prior art date
Application number
PE2005001440A
Other languages
English (en)
Inventor
Massimiliana Landini
Sandro Giuliani
Alessandro Giolitti
Original Assignee
Menarini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20042371 external-priority patent/ITMI20042371A1/it
Priority claimed from ITMI20051739 external-priority patent/ITMI20051739A1/it
Application filed by Menarini Ricerche Spa filed Critical Menarini Ricerche Spa
Publication of PE20060746A1 publication Critical patent/PE20060746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LA PDE3 COMO PRINCIPIO ACTIVO. DICHO PRINCIPIO ACTIVO PUEDE SER ANAGRELIDA, CILOSTAZOL, PIMOBENDAN, MILRINONA, 6-[4-(2-BENCIL-3-OXO-CICLOHEX-1-ENILAMINO)-FENIL]-5-METIL-4,5-DIHIDRO-2-H-PIRIDAZIN-3-ONA, 3-{2-[4-(4,4-DIMETIL-5-OXO-4,5-DIHIDRO-1-H-PIRAZOL-3-IL)-2,3-DIFLUORO-FENILAMINO]-6-OXO-CICLOHEX-1-ENILMETIL}-BENZONITRILO, ENTRE OTROS. EL COMPUESTO ACTIVO SE ENCUENTRA ENTRE 0,1% Y 3% EN PESO. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA CELULITIS Y PUEDE ESTAR BAJO LA FORMA DE GEL, SPRAY GEL, GREMA, CREMA NO OLEOSA, FORMULACION ACEITE NO ACEITE, UNGUENTO O VENDAJE ADHESIVO Y ADEMAS, PUEDE CONTENER UNA MEZCLA DE SUSTANCIAS O UN EXTRACTO CON ACTIVIDAD SOBRE LA MICROCIRCULACION TALES COMO EXTRACTO DE ARNICA, GINKGO BILOBA, CENTELLA ASIATICA, ENTRE OTROS, EN UNA CANTIDAD DE ENTRE 0,1% Y 4% EN PESO
PE2005001440A 2004-12-14 2005-12-13 Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3 PE20060746A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20042371 ITMI20042371A1 (it) 2004-12-14 2004-12-14 Composizioni farmaceutiche topiche per il trattamento della cellulite
ITMI20051739 ITMI20051739A1 (it) 2005-09-20 2005-09-20 Composizioni farmaceutiche topiche per il trattamento della cellulite

Publications (1)

Publication Number Publication Date
PE20060746A1 true PE20060746A1 (es) 2006-09-06

Family

ID=35708888

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001440A PE20060746A1 (es) 2004-12-14 2005-12-13 Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3

Country Status (18)

Country Link
US (1) US20100016324A1 (es)
EP (1) EP1824463A1 (es)
JP (1) JP2008523127A (es)
KR (1) KR20070086101A (es)
AR (1) AR052048A1 (es)
AU (1) AU2005315919B2 (es)
BR (1) BRPI0518554A2 (es)
CA (1) CA2590288A1 (es)
HK (1) HK1111599A1 (es)
IL (1) IL183893A0 (es)
MA (1) MA29145B1 (es)
MX (1) MX2007007015A (es)
NO (1) NO20073575L (es)
NZ (1) NZ555836A (es)
PE (1) PE20060746A1 (es)
RU (1) RU2401098C2 (es)
TN (1) TNSN07203A1 (es)
WO (1) WO2006063714A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100963268B1 (ko) 2006-11-22 2010-06-11 에스케이케미칼주식회사 실로스타졸과 은행잎 추출물을 함유한 약제 조성물
ITMI20070604A1 (it) 2007-03-26 2008-09-27 Menarini Farma Ind Preparazioni cosmetiche per la riduzione degli inestetismi della cellulite
CN102341109A (zh) * 2009-03-02 2012-02-01 多丽丝·赫克斯塞尔 医学美容脂肪萎缩
MY170724A (en) 2012-01-27 2019-08-27 Biotropics Malaysia Berhad Use of certain trioxygenated benzene derivatives in body fat management
CN104161756B (zh) * 2014-06-13 2017-02-01 河北智同医药控股集团有限公司 一种盐酸奥普力农注射液组合物
EA031658B1 (ru) * 2017-06-30 2019-02-28 Акционерное Общество "Верофарм" Антицеллюлитный косметический комплекс
RU2694898C1 (ru) * 2018-08-29 2019-07-18 Талагаева Елена Владимировна Крем для лица и тела

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147497A (en) 1977-01-04 1979-04-03 Gte Sylvania Incorporated Hand-operable signal device using percussively-ignitable flashlamps
IT1270602B (it) 1994-07-12 1997-05-07 Indena Spa Formulazioni a base di esculoside e loro uso in campo farmaceutico e cosmetico
JP3452986B2 (ja) * 1994-09-13 2003-10-06 花王株式会社 脂肪分解促進剤
JP4182183B2 (ja) 1999-08-24 2008-11-19 ディーエスエム アイピー アセッツ ビー．ブイ． 痩身用皮膚化粧料
FR2802811B1 (fr) * 1999-12-24 2002-02-15 Silab Sa Procede d'extraction d'un principe actif a partir de petales de bigarade, notamment pour le traitement de la cellulite, principe actif obtenu, compositions cosmetiques et traitements adaptes
WO2001060331A2 (en) * 2000-02-15 2001-08-23 Zen-Bio, Inc. Compositions for preventing cellulite in mammalian skin
DE10009423A1 (de) 2000-02-28 2001-09-06 Henkel Kgaa Kosmetische und pharmazeutische Zubereitungen
DE10009424A1 (de) 2000-02-28 2001-09-06 Henkel Kgaa Verwendung von Flavonen oder Isoflavonen zur Cellulite-Behandlung
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat

Also Published As

Publication number Publication date
NZ555836A (en) 2009-09-25
AU2005315919B2 (en) 2011-06-09
HK1111599A1 (en) 2008-08-15
EP1824463A1 (en) 2007-08-29
JP2008523127A (ja) 2008-07-03
RU2007120465A (ru) 2009-01-27
CA2590288A1 (en) 2006-06-22
MX2007007015A (es) 2007-07-04
TNSN07203A1 (en) 2008-11-21
US20100016324A1 (en) 2010-01-21
AR052048A1 (es) 2007-02-28
AU2005315919A1 (en) 2006-06-22
WO2006063714A1 (en) 2006-06-22
NO20073575L (no) 2007-09-13
RU2401098C2 (ru) 2010-10-10
KR20070086101A (ko) 2007-08-27
IL183893A0 (en) 2007-10-31
BRPI0518554A2 (pt) 2008-11-25
MA29145B1 (fr) 2008-01-02

Similar Documents

Publication Publication Date Title
PE20110449A1 (es) Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
AR057554A1 (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
WO2009100441A3 (en) Depot formulations
CL2007002743A1 (es) Forma cristalina del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico; composicion farmaceutica que comprende a dicha forma cristalina; y su uso para modular la terminacion prematura de traslado o decaimiento de marn, tales como carcicoma.
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
PE20131464A1 (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
AR070018A1 (es) 5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il sulfamida, composiciones farmaceuticas que lo contienen, metodo de preparacion y uso del mismo en enfermedades asociadas al aumento de la vasoconstriccion, proliferacion o inflamacion debidas a endotelina, tales como insuficien
AR068921A1 (es) Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NI200700189A (es) Ciclopropil -(2,3-dimetilbencil)amidos del ácido 7-{4-[2-(2,6-dicloro-4-metilfenoxi)- etoxi]fenil}-3,9- diazabiciclo [3.3.1]non-6-en-6-carboxílico como inhibidores de renina para el tratamiento de la hipertensión.
EP2348018A4 (en) HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
PE20060746A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
PE20070430A1 (es) Composiciones topicas que comprenden o-desmetilvenlafaxina (odv)
PE20061365A1 (es) Composiciones farmaceuticas de liberacion modificada
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
PE20081794A1 (es) Composicion farmaceutica que comprende un agente calcilitico
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载